Concepedia

Author

Hugo Maas

Boehringer Ingelheim (Germany)

Also Known As

H MAAS, H. J. Maas, H. Maas, H.J. Maas, Hugo J Maas, Hugo J. Maas, Hugo Maas

25

Publications

2.4K

Citations

14

H-Index

34

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Centre for Human Drug ResearchUniversity of MannheimHeidelberg University
HM

About

Hugo Maas is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacotherapy, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

132

2

Biostatistics

2

2

26

3

Engineering

1

1

11

4

Public Health

1

1

15

5

Social Sciences

1

1

49

Hugo Maas

×

15

Publications

2.4K

Citations

13

H-Index

YearCitations

Dabigatran versus Warfarin in Patients with Mechanical Heart Valves

John W. Eikelboom, Stuart J. Connolly, Martina Brueckmann,

New England Journal of Medicine

2013

1.5K

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Lena E. Friberg, Anja Henningsson, Hugo Maas,

Journal of Clinical Oncology

2002

523

A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia

Klaas P. Zuideveld, Hugo Maas, Nicoline Treijtel,

American Journal of Physiology-Regulatory, Integrative and Comparative Physiology

2001

49

Generating Virtual Patients by Multivariate and Discrete Re-Sampling Techniques

Donato Teutonico, Flora T. Musuamba, Hugo Maas,

Pharmaceutical Research

2015

43

A Competitive Interaction Model Predicts the Effect of WAY-100,635 on the Time Course of R -(+)-8-Hydroxy-2-(di-n-propylamino)tetralin-Induced Hypothermia

Klaas P. Zuideveld, Nicoline Treijtel, Hugo Maas,

Journal of Pharmacology and Experimental Therapeutics

2002

35

Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment

G.L. Li, Joeke J. de Vries, Tamara J. van Steeg,

Journal of Controlled Release

2004

34

Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability

Jacqueline ML Halton, Manuela Albisetti, Branislav Biss,

Journal of Thrombosis and Haemostasis

2017

34

Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

Klaas P. Zuideveld, Jasna Rusiç-Pavletiç, Hugo Maas,

Journal of Pharmacology and Experimental Therapeutics

2002

33

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate Oral Liquid Formulation in Infants with Venous Thromboembolism

Jacqueline ML Halton, Anne-Caroline Picard, Ruth Harper,

Thrombosis and Haemostasis

2017

29

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients

Daniel Moj, Hugo Maas, André Schaeftlein,

Clinical Pharmacokinetics

2019

23

Page 1